生物制药公司Atossa Therapeutics宣布，其研发药物(Z)-Endoxifen用于治疗McCune-Albright综合征（MAS）已获得美国食品药品监督管理局（FDA）颁发的罕见儿科疾病认定（RPDD）。
该认定将为Atossa公司在药物后续研发与商业化进程中提供政策支持。McCune-Albright综合征是一种极为罕见的遗传性疾病，目前临床治疗选择有限。(Z)-Endoxifen作为选择性雌激素受体调节剂，有望为患者提供新的治疗方向。
生物制药公司Atossa Therapeutics宣布，其研发药物(Z)-Endoxifen用于治疗McCune-Albright综合征（MAS）已获得美国食品药品监督管理局（FDA）颁发的罕见儿科疾病认定（RPDD）。
该认定将为Atossa公司在药物后续研发与商业化进程中提供政策支持。McCune-Albright综合征是一种极为罕见的遗传性疾病，目前临床治疗选择有限。(Z)-Endoxifen作为选择性雌激素受体调节剂，有望为患者提供新的治疗方向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.